IL149488A0 - Pharmaceutical compositions containing aplidine - Google Patents

Pharmaceutical compositions containing aplidine

Info

Publication number
IL149488A0
IL149488A0 IL14948800A IL14948800A IL149488A0 IL 149488 A0 IL149488 A0 IL 149488A0 IL 14948800 A IL14948800 A IL 14948800A IL 14948800 A IL14948800 A IL 14948800A IL 149488 A0 IL149488 A0 IL 149488A0
Authority
IL
Israel
Prior art keywords
aplidine
pharmaceutical compositions
compositions containing
tumor
containing aplidine
Prior art date
Application number
IL14948800A
Other languages
English (en)
Original Assignee
Pharma Mar Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9927006.8A external-priority patent/GB9927006D0/en
Priority claimed from GB0005701A external-priority patent/GB0005701D0/en
Priority claimed from GB0007639A external-priority patent/GB0007639D0/en
Priority claimed from GB0015496A external-priority patent/GB0015496D0/en
Priority claimed from GB0025209A external-priority patent/GB0025209D0/en
Application filed by Pharma Mar Sa filed Critical Pharma Mar Sa
Publication of IL149488A0 publication Critical patent/IL149488A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/15—Depsipeptides; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyrrole Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
IL14948800A 1999-11-15 2000-11-15 Pharmaceutical compositions containing aplidine IL149488A0 (en)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
GBGB9927006.8A GB9927006D0 (en) 1999-11-15 1999-11-15 Aplidine treatment of cancers
GB0005701A GB0005701D0 (en) 2000-03-09 2000-03-09 Antitumor utility of aplidine
GB0007639A GB0007639D0 (en) 2000-03-29 2000-03-29 Antitumour and anti-angiogenic compound
GB0015496A GB0015496D0 (en) 2000-06-23 2000-06-23 Antitumour and anti-angiogenic compound
GB0025209A GB0025209D0 (en) 2000-10-13 2000-10-13 Treatment of cancers
PCT/GB2000/004349 WO2001035974A2 (en) 1999-11-15 2000-11-15 Aplidine treatment of cancers

Publications (1)

Publication Number Publication Date
IL149488A0 true IL149488A0 (en) 2002-11-10

Family

ID=27515929

Family Applications (1)

Application Number Title Priority Date Filing Date
IL14948800A IL149488A0 (en) 1999-11-15 2000-11-15 Pharmaceutical compositions containing aplidine

Country Status (27)

Country Link
US (1) US20090298752A1 (https=)
EP (1) EP1229922B1 (https=)
JP (1) JP2003514025A (https=)
KR (1) KR100518986B1 (https=)
CN (1) CN1423564A (https=)
AT (1) ATE363910T1 (https=)
AU (1) AU780417B2 (https=)
BG (1) BG65381B1 (https=)
BR (1) BR0015811A (https=)
CA (1) CA2391502A1 (https=)
CY (1) CY1106825T1 (https=)
CZ (1) CZ302498B6 (https=)
DE (1) DE60035120T2 (https=)
DK (1) DK1229922T3 (https=)
ES (1) ES2288486T3 (https=)
HK (1) HK1045648B (https=)
HU (1) HUP0203906A2 (https=)
IL (1) IL149488A0 (https=)
MX (1) MXPA02004862A (https=)
NO (1) NO330719B1 (https=)
NZ (1) NZ518847A (https=)
PL (1) PL200922B1 (https=)
PT (1) PT1229922E (https=)
RU (1) RU2261104C2 (https=)
SI (1) SI1229922T1 (https=)
SK (1) SK287762B6 (https=)
WO (1) WO2001035974A2 (https=)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030148933A1 (en) 1990-10-01 2003-08-07 Pharma Mar S.A. Derivatives of dehydrodidemnin B
GB9803448D0 (en) 1998-02-18 1998-04-15 Pharma Mar Sa Pharmaceutical formulation
UA76718C2 (uk) 2000-06-30 2006-09-15 Фарма Мар, С.А. Протипухлинні похідні аплідину
CZ2003993A3 (cs) 2000-10-12 2004-02-18 Pharma Mar, S. A. Léčivo pro léčení rakoviny podáváním aplidinu nebo analogu aplidinu a protektoru kosterního svalstva
WO2003033013A1 (en) * 2001-10-19 2003-04-24 Pharma Mar, S.A. Use of aplidine for the treatment of pancreatic cancer
BR0213424A (pt) * 2001-10-19 2004-12-14 Pharma Mar Sa Uso aperfeiçoado de composto antitumoral na terapia contra câncer
WO2004080421A2 (en) * 2003-03-12 2004-09-23 Pharma Mar, S.A. Improved antitumoral treatments
ATE406171T1 (de) * 2003-03-12 2008-09-15 Dana Farber Cancer Inst Inc Aplidine zur behandlung von multiplem myelom
CN101389347B (zh) * 2006-02-28 2013-03-27 法马马有限公司 提高的抗肿瘤治疗
JP5547487B2 (ja) * 2006-11-03 2014-07-16 ネルビアーノ・メデイカル・サイエンシーズ・エツセ・エルレ・エルレ 抗癌化合物の投与方法
RU2360712C1 (ru) * 2007-10-02 2009-07-10 Федеральное государственное учреждение "Ростовский научно-исследовательский онкологический институт Росмедтехнологий" Способ лечения местно-распространенного неоперабельного рака прямой кишки
AU2008313627A1 (en) * 2007-10-19 2009-04-23 Pharma Mar, S.A. Improved antitumoral treatments
US20110009335A1 (en) * 2008-03-07 2011-01-13 Pharma Mar, S.A. Anticancer Treatments
CN103463020B (zh) * 2013-09-23 2015-11-25 李淑兰 Lycojaponicumin A在制备治疗肾癌药物中的应用
HRP20231233T1 (hr) 2017-04-27 2024-01-19 Pharma Mar, S.A. Antitumorski spojevi

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4342744A (en) * 1979-07-19 1982-08-03 Lever Brothers Company Hair treatment products
DE3161556D1 (en) * 1980-09-12 1984-01-05 Univ Illinois Novel antibiotics, derivatives thereof, processes for their extraction, and compositions containing them
US4950649A (en) * 1980-09-12 1990-08-21 University Of Illinois Didemnins and nordidemnins
US4493796A (en) * 1980-09-12 1985-01-15 Board Of Trustees, Univ. Of Ill. Didemnins A, B, C, and derivatives thereof, as antiviral agents
IT1153974B (it) * 1982-09-23 1987-01-21 Erba Farmitalia Composizioni farmacologiche a base di cisplatino e metodo per il loro ottenimento
ATE74761T1 (de) * 1985-09-20 1992-05-15 Cernitin Sa Verwendung von pflanzenpollenextrakten zur herstellung von das wachstum von tumorzellen hemmenden pharmazeutischen praeparaten und verfahren zu ihrer herstellung.
GB8922026D0 (en) * 1989-09-29 1989-11-15 Pharma Mar Sa Novel anti-viral and cytotoxic agent
US20030148933A1 (en) * 1990-10-01 2003-08-07 Pharma Mar S.A. Derivatives of dehydrodidemnin B
US5580871A (en) * 1992-11-20 1996-12-03 The Dupont Merck Pharmaceutical Company 4-Heteroaryl- 1,4-dihydropyridine compounds with calcium agonist and alpha1 -antagonist activity
FR2698543B1 (fr) * 1992-12-02 1994-12-30 Rhone Poulenc Rorer Sa Nouvelles compositions à base de taxoides.
US5462726A (en) * 1993-12-17 1995-10-31 Bristol-Myers Squibb Company Method of inhibiting side effects of solvents containing ricinoleic acid or castor oil or derivatives thereof employing a thromboxane A2 receptor antagonist and pharmaceutical compositions containing such solvents
JPH09507233A (ja) * 1993-12-29 1997-07-22 マトリクス ファーマスーティカル，インコーポレイティド 細胞増殖性疾患に罹る宿主の治療方法及び治療のための組成物
US5861439A (en) * 1994-11-14 1999-01-19 Alza Corporation Method for enhanced electrotransport agent delivery
US6365597B1 (en) * 1996-02-14 2002-04-02 Aventis Pharmaceuticals Inc. 4-aza steroids
US5795909A (en) * 1996-05-22 1998-08-18 Neuromedica, Inc. DHA-pharmaceutical agent conjugates of taxanes
WO1997044026A1 (en) * 1996-05-22 1997-11-27 Neuromedica, Inc. Compositions comprising conjugates of cis-docosahexaenoic acid and taxotere
US6156724A (en) * 1996-06-07 2000-12-05 Rinehart; Kenneth L. Uses of didemnins as immunomodulating agents
US6034058A (en) * 1997-04-15 2000-03-07 Rinehart; Kenneth L. Semi-synthetic alanyl dilemnin analogs
EP0981352B8 (en) * 1997-05-07 2009-06-17 Pharma Mar, S.A. Use of aplidine for the treatment of cardiovascular diseases
US6245759B1 (en) * 1999-03-11 2001-06-12 Merck & Co., Inc. Tyrosine kinase inhibitors
US20010021380A1 (en) * 1999-04-19 2001-09-13 Pluenneke John D. Soluble tumor necrosis factor receptor treatment of medical disorders
US6890904B1 (en) * 1999-05-25 2005-05-10 Point Therapeutics, Inc. Anti-tumor agents
ES2272462T3 (es) * 2000-04-07 2007-05-01 The Trustees Of The University Of Pennsylvania Analogos de tamadarina y didemnina y procedimiento de fabricacion y uso.
US6509315B1 (en) * 2000-04-07 2003-01-21 The Trustees Of The University Of Pennsylvania Didemnin analogs and fragments and methods of making and using them
UA76718C2 (uk) * 2000-06-30 2006-09-15 Фарма Мар, С.А. Протипухлинні похідні аплідину
MXPA03002479A (es) * 2000-10-05 2004-05-24 Immunex Corp Polipeptidos de nectina, polinucleotidos, metodos para elaborarlos y uso de los mismos.
CZ2003993A3 (cs) * 2000-10-12 2004-02-18 Pharma Mar, S. A. Léčivo pro léčení rakoviny podáváním aplidinu nebo analogu aplidinu a protektoru kosterního svalstva
AU2002224417A1 (en) * 2000-10-18 2002-04-29 Immunex Corporation Methods for treating il-18 mediated disorders
US6610399B1 (en) * 2000-11-17 2003-08-26 Structural Technologies, Llc Multi-layer, thermal protection and corrosion protection coating system for metallic tendons, especially for external post-tensioning systems
WO2003033013A1 (en) * 2001-10-19 2003-04-24 Pharma Mar, S.A. Use of aplidine for the treatment of pancreatic cancer
ATE406171T1 (de) * 2003-03-12 2008-09-15 Dana Farber Cancer Inst Inc Aplidine zur behandlung von multiplem myelom
WO2004080421A2 (en) * 2003-03-12 2004-09-23 Pharma Mar, S.A. Improved antitumoral treatments
CA2519234A1 (en) * 2003-03-21 2004-10-07 Madeleine M. Joullie Tamandarin analogs and fragments thereof and methods of making and using
EP1639090A4 (en) * 2003-06-09 2008-04-16 Univ Michigan COMPOSITIONS AND METHODS OF TREATMENT AND DIAGNOSIS OF CANCER
CN101389347B (zh) * 2006-02-28 2013-03-27 法马马有限公司 提高的抗肿瘤治疗
AU2008313627A1 (en) * 2007-10-19 2009-04-23 Pharma Mar, S.A. Improved antitumoral treatments

Also Published As

Publication number Publication date
CN1423564A (zh) 2003-06-11
CA2391502A1 (en) 2001-05-25
AU1402301A (en) 2001-05-30
BG65381B1 (bg) 2008-05-30
PL355335A1 (en) 2004-04-19
NO330719B1 (no) 2011-06-20
MXPA02004862A (es) 2003-01-28
US20090298752A1 (en) 2009-12-03
ATE363910T1 (de) 2007-06-15
NO20022293D0 (no) 2002-05-14
CZ302498B6 (cs) 2011-06-15
ES2288486T3 (es) 2008-01-16
PL200922B1 (pl) 2009-02-27
BR0015811A (pt) 2002-08-06
PT1229922E (pt) 2007-09-12
AU780417B2 (en) 2005-03-17
BG106714A (en) 2003-02-28
CZ20021697A3 (cs) 2003-02-12
HK1045648B (en) 2007-09-21
NO20022293L (no) 2002-07-05
NZ518847A (en) 2004-02-27
RU2002115864A (ru) 2004-01-20
SK287762B6 (sk) 2011-09-05
HK1045648A1 (en) 2002-12-06
WO2001035974A3 (en) 2001-11-01
SK6592002A3 (en) 2003-08-05
JP2003514025A (ja) 2003-04-15
KR20020064313A (ko) 2002-08-07
DE60035120D1 (de) 2007-07-19
EP1229922B1 (en) 2007-06-06
EP1229922A2 (en) 2002-08-14
RU2261104C2 (ru) 2005-09-27
SI1229922T1 (sl) 2008-04-30
KR100518986B1 (ko) 2005-10-06
DE60035120T2 (de) 2008-01-31
DK1229922T3 (da) 2007-10-08
WO2001035974A2 (en) 2001-05-25
HUP0203906A2 (en) 2003-03-28
CY1106825T1 (el) 2012-05-23

Similar Documents

Publication Publication Date Title
IL149488A0 (en) Pharmaceutical compositions containing aplidine
HUP0203238A3 (en) Drugs for the treatment of malignant tumours, process for their preparation and pharmaceutical compositions containing them
PL354540A1 (en) Drugs for the treatment of malignant tumours
TW581808B (en) Compounds for immunotherapy of prostate cancer and methods for their use
AU5089799A (en) Drug complex for treatment of metastatic prostate cancer
WO2004045532A3 (en) Methods for preventing and treating cancer metastasis and bone loss associated with cancer metastasis
IL138330A0 (en) Polynucleotides, polypeptides and pharmaceutical compositions for treating lung cancer
WO1999038973A3 (en) Compounds for therapy and diagnosis of lung cancer and methods for their use
HUP0301046A3 (en) Quinazoline derivatives for the treatment of tumours, process for their preparation and pharmaceutical compositions containing them
WO1999033869A3 (en) Compounds for immunotherapy and diagnosis of breast cancer and methods for their use
WO1999043355A3 (en) Formulations containing oxaliplatin
YU69903A (sh) Postupak i dozni oblik za lečenje tumora primenom tegafura, uracila, folne kiseline, paklitaksela i karboplatina
MXPA04003674A (es) Uso mejorado de compuesto antitumoral en terapia de cancer.
WO2000061756A3 (en) Compounds for immunotherapy and diagnosis of breast cancer and methods for their use
MXPA02005045A (es) Preparaciones farmaceuticas que contiene agentes citostaticos y aceptores de electrones para el tratamiento de cancer.
BG108932A (en) Pharmaceutical composition comprising arsenite for the treatment of malignancy
ZA200106725B (en) Use of an enterobacterium protein ompa associated with an antigen for generating an antiviral antiparasitic or antitumoral cytotoxic response.
AU5302599A (en) Method for diagnosing bone metastasis of malignant tumor
WO1999056697A3 (en) Pharmaceutical composition
IL160382A0 (en) Use of 4-pyridylmethylphthalazines for cancer treatment
MY133682A (en) Substituted pyrroles
WO2000030587A3 (fr) INHIBITEURS DE L'ACTIVATION DE NF-λB, ET LEURS UTILISATIONS PHARMACEUTIQUES
AU1991901A (en) Pharmaceutical composition for treating and preventing human tumors, which express the tumor antigen mucin and/or the carcinoembryonic antigen (cea), and the use thereof
AU2001256440A1 (en) Medicines for treating tumoral pathologies containing the ro5-4864 compound and an apoptosis-inducing agent
WO2004098651A3 (en) Bone localising radiopharmaceutical and tubulin-interacting compound combinatorial radiotherapy